4.8 Nonprescription, Behind-the-Counter & Restricted OTC Sales

Nonprescription, Behind-the-Counter & Restricted OTC Dispensing

Competency Area 3 (Dispensing Requirements, 24% of the MPJE) includes 3.8 — Requirements for the distribution and/or dispensing of non-prescription pharmaceutical products, including controlled substances and hazardous drugs. Sub-bullets cover dispensing/administration, OTC labeling, packaging/repackaging of nonprescription and behind-the-counter (BTC) products, and dispensing-restricted nonprescription drugs. Georgia candidates must layer federal Combat Methamphetamine Epidemic Act (CMEA) rules, Georgia Board Chapter 480-19, and O.C.G.A. § 16-13-30.3 electronic-logging duties—not a generic “OTC is unregulated” mindset.

Why Nonprescription Content Still Hits Hard on the Georgia MPJE

Patients assume anything without a prescription is aisle candy. In practice, pharmacies gatekeep products that can be diverted (pseudoephedrine/ephedrine), abused (exempt Schedule V cough preparations where still permitted), or mishandled (expired insulin, recalled cough/cold stock, misbranded social-media “protocols”). Exam stems typically ask: Who may complete the sale? Where must the product be stored? What ID/logbook fields are required? What daily and 30-day gram limits apply? When must a stop-sale alert block the transaction?

Georgia Pseudoephedrine / Ephedrine Controls (Highest Yield)

Federal CMEA regulates retail sales of scheduled listed chemical products (SCLPs) such as pseudoephedrine and ephedrine. Georgia Board Rule 480-19-.03 and O.C.G.A. § 16-13-30.3 make the Georgia retail workflow stricter and more pharmacist-centered than a bare federal summary.

Storage and who may sell (Georgia-specific)

• Exempt Schedule V pseudoephedrine-containing products must be stored in the pharmacy’s prescription department—not ordinary open aisle stock.
• Sales may be made by a registered pharmacist, or a pharmacy intern/extern under direct supervision of a registered pharmacist. Cashier-only impulse sales fail both Chapter 480-19 and CMEA intent.
• Pharmacy personnel who sell these products must complete DEA CMEA self-certification training.

Quantity limits (federal baseline mirrored in Georgia rule)

• Not more than 3.6 grams every 24 hours and not more than 9 grams every 30 days of pseudoephedrine base to each customer.
• Limits are based on base content, not bottle count. Board tables convert common strengths (example: 60 mg pseudoephedrine HCl ≈ 73 tablets for the 3.6 g daily limit; ≈ 183 tablets for the 9 g / 30-day limit). Know to use the conversion table rather than guessing pack sizes.
• Federal CMEA historically exempts single sales packages containing ≤ 60 mg pseudoephedrine from some logbook formalities, but those packages still must stay behind the counter. Prefer the stricter applicable Georgia process when systems conflict.

Identification, approval, and logbook (Rule 480-19-.03)

Before completing a sale, the pharmacist (or supervised intern/extern) must apply reasonable effort to confirm a legitimate medical purpose, verify government-issued photo ID, and ensure required information is recorded in a written or electronic logbook. Minimum recorded elements typically include:

• Purchaser name, date of birth, address/ZIP
• Product name, strength, and quantity sold
• Date and time of sale
• Purchaser signature (wet ink or electronic capture comparable to credit-card signature pads)
• Seller verification initials/ID confirming the entry is correct

No photo ID → no sale. Structured “smurfing” attempts, refusal to sign, or diversion red flags warrant refusal and pharmacy diversion-policy follow-up.

Real-time electronic logging (O.C.G.A. § 16-13-30.3)

On and after January 1, 2017, Georgia pharmacies must electronically track nonprescription ephedrine/pseudoephedrine sales in a GBI-approved real-time electronic logging system (historically rolled out as GANPLEx / Georgia Meth Watch) before completing the sale.

• If the system generates a stop-sale alert, do not complete the sale except for the narrow statutory override when the seller reasonably fears imminent bodily harm (override sales are tracked).
• If the electronic system fails mechanically, maintain a written log or alternative electronic recording until the real-time system is restored.
• Required transmitted information includes purchaser identity/address, ID type/issuer/number, product description with grams of pseudoephedrine, and date/time.
• Retain sale records for two years. Board Rule 480-19-.04 requires records to be readily retrievable: generally < 6 hours for electronic records and 24 hours for handwritten records when GDNA/law enforcement requests them. Centralized/third-party storage needs prior GDNA approval and a notified point of contact.

A single logbook may satisfy both CMEA and Georgia requirements if it captures all required fields—but Georgia still demands prescription-department storage and pharmacist/intern/extern gatekeeping.

Exempt Non-Pseudoephedrine Schedule V OTC Sales (Chapter 480-19-.01 / .02)

Separate from PSE, Georgia still regulates non-pseudoephedrine exempt Schedule V OTC sales (historically certain codeine-containing cough preparations meeting exempting conditions):

• A licensed pharmacist, or intern under immediate and direct pharmacist supervision, may sell without a prescription not more than 4 oz or 32 dosage units within any 48-hour period, after confirming legitimate medical purpose and completing the purchaser register (signature, DOB, address, date, product/quantity/intended use).
• Purchasers may not obtain more than those same limits in a 48-hour period.
• Before selling, confirm the manufacturer package is truly OTC-exempt: if the label bears a Federal Caution, Warning, or Rx Only legend, it is not an exempt OTC sale—dispense only pursuant to a prescription and file as a controlled-substance prescription.
• This is never a front-end cashier transaction. When conditions are not met, require a prescription.

Because formulation lists change, prioritize the control process (pharmacist gatekeeping + quantity/age/record rules) over memorizing every brand.

Ordinary OTC Labeling, Packaging & Pharmacy Duties

Even “true” OTCs engage FDCA concepts tested under Area 3.8:

• Misbranding if required Drug Facts, directions, or warnings are missing, or if staff make unapproved disease claims at the counter.
• Adulteration if products are expired, contaminated, or stored outside labeled temperature ranges.
• Pharmacists must quarantine recalls and refuse illegal distribution of unapproved “internet protocol” products marketed as OTCs.
• BTC placement may also be used for non-CMEA store-policy items; distinguish law from policy when answering stems.

Hazardous Nonprescription Products & Special Populations

Area 3.8 also references hazardous drugs in nonprescription distribution contexts. Retail staff must prevent public access to hazardous investigational or bulk chemicals and follow disposal rules. For pregnant patients requesting misbranded abortifacient “kits” or unsafe social-media regimens, refuse illegal distribution and provide lawful clinical referral information rather than facilitating unapproved drug sales.

Georgia Practice Integration Scenarios

Technicians may assist with data entry or retrieval only after pharmacist/intern/extern approval under the pharmacy’s compliant process—they do not independently override hard stops or quantity limits.

Quick Comparison Table

Nonprescription status never means “no pharmacist duty.” On the Georgia MPJE, treat BTC and restricted OTC sales as regulated dispensing events with identity, quantity, documentation, electronic stop-sale, and professional-judgment checkpoints.